In order to develop treatments and effective interventions for patients with FTD, the underlying process of brain degeneration needs to be identified early in the disease course. FTD patients may have one of several different underlying brain pathologies which cannot at present be predicted by either the type of symptoms exhibited, or by a genetic profile. Cellular studies of the brain have shown that there are two types of protein (tau
